We are live on ! Find out more
IPHA

Innate Pharma
IPHA

9 hedge funds and large institutions have $736K invested in Innate Pharma in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 9 → 9 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.2% less ownership

Funds ownership: 0.49% → 0.29% (-0.2%)

35% less capital invested

Capital invested by funds: $1.13M → $736K (-$393K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
9
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ETC
Exchange Traded Concepts
Oklahoma
+$130K
2
Citadel Advisors
Citadel Advisors
Florida
+$40.8K
3
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$630

Top Sellers

Rank Fund Capital Flow
1
Optiver Holding
Optiver Holding
Netherlands
-$437K
2
Bank of America
Bank of America
North Carolina
-$133K
3
Millennium Management
Millennium Management
New York
-$38.3K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$37.8K
5
Morgan Stanley
Morgan Stanley
New York
-$5.14K

IPHA Hedge Fund Activity: Q2 2023 in Review

9 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q2 2023, worth a combined $736K — down 35% from $1.13M a quarter earlier.

Fund positioning in IPHA was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 4 trimmed.

The largest buyer was Exchange Traded Concepts, opening a new position worth an estimated $130K. The largest seller was Optiver Holding, cutting an estimated $437K.

  • 9 institutional investors held Innate Pharma (IPHA) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $736K of Innate Pharma stock for Q2 2023, down 35% quarter-over-quarter.
  • 3 funds opened new Innate Pharma positions in Q2 2023 and 3 closed out, a net change of 0 holders.
  • The largest Innate Pharma buyer in Q2 2023 was Exchange Traded Concepts, an estimated $130K added.
  • The largest Innate Pharma seller in Q2 2023 was Optiver Holding, an estimated $437K sold.

Based on aggregated 13F filings for Q2 2023.